Jafron Biomedical Co

Jafron Biomedical Co Short-term Debt

The Short-Term Debt of Jafron Biomedical Co (300529.SZ) as of Nov 19, 2026 is 77.51 M CNY. In the previous year, Short-Term Debt was 261.83 M CNY — a change of -70.40% (lower).

Short-term Debt

77.51 MCNY

YoY

-70.40%

Last updated:

Short-Term Debt of Jafron Biomedical Co is 2024 77.51 M CNY. Short-Term Debt of Jafron Biomedical Co was 2023 261.83 M CNY. It decreases by -70.40% lower compared to the previous year.

The Jafron Biomedical Co Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2022
317.09 M CNY
Jan 1, 2023
261.83 M CNY
Jan 1, 2024
77.51 M CNY
The Jafron Biomedical Co Short-term Debt history
YEARShort-term DebtYoY
77.51 MCNY-70.40%
261.83 MCNY-17.43%
317.09 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Short-Term Debt of Jafron Biomedical Co is 77.51 M CNY in 2024.

Short-Term Debt of Jafron Biomedical Co changed from 261.83 M CNY to 77.51 M CNY, representing a -70.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co